



File No. BIO/CT/24/000149

Dated 20-05-2025

To

M/s G.C.Chemie Pharmie Ltd.,  
5C Laxmi Industrial Estate, New Link Road  
Andheri(West)MUMBAI (India) - 400053.

Subject: Application for grant of permission to conduct Phase I Clinical trial titled –“A double blind, balanced, randomized, two-treatment, two-sequence, two-period, single dose, crossover, pharmacokinetic and pharmacodynamic bioequivalence study of insulin degludec and insulin aspart injection 100 units/mL of G. C Chemie Pharmie Limited, India comparing with Ryzodeg (Insulin degludec/Insulin aspart)100 units/mL of Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd, Denmark, in healthy, adult, human male subjects using Euglycemic clamp technique under fasting conditions” vide protocol number no.: AR136-24Version 01 dated 24 Oct 2024– regarding.

Ref.: Your Application No BIO/CT04/FF/2024/46221 dated 15-11-2024.

Sir,

With reference to your Application No. BIO/CT04/FF/2024/46221 dated 15-11-2024, please find enclosed herewith the permission in Form CT-06 for conduct of subject clinical trial under the provisions of New Drugs and Clinical Trial Rules, 2019. Further the firm has to submit bioanalytical method before initiation of the trial.

The permission granted by the Central Licensing Authority to conduct clinical trial under this Chapter shall be subject to following conditions, namely:

- (I) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licensing Authority under rule 8;
- (II) Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7:  
Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:  
Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;
- (III) In case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;
- (IV) The Central Licensing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;
- (V) Clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;
- (VI) Clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;

- (VII) Status of enrolment of the trial subjects shall be submitted to the Central Licensing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;
- (VIII) Six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licensing Authority electronically in the SUGAM portal;
- (IX) In case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licensing Authority within thirty working days of such termination;
- (X) Any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licensing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI;
- (XI) In case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licensing Authority within thirty working days of the receipt of order issued by Central Licensing Authority in accordance with the provisions of the said Chapter;
- (XII) In case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licensing Authority within thirty working days of receipt of the order issued by the Central Licensing Authority in accordance with the provisions of the said Chapter;
- (XIII) The premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licensing Authority who may be accompanied by officers of the State Licensing Authority or outside experts as authorised by the Central Licensing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;
- (XIV) The laboratory owned by any person or a company or any other legal entity and utilised by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licensing Authority and may be used for test or analysis of any drug for and on behalf of Central Licensing Authority;
- (XV) The Central Licensing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;
- (XVI) The sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.
- (XVII) where the new drug or investigational new drug is found to be useful in clinical development, the sponsor shall submit an application to the Central Licencing Authority for permission to import or manufacture for sale or for distribution of new drug in India, in accordance with Chapter X of these rules, unless otherwise justified.
- (XVIII) It may kindly be noted that merely granting permission to conduct clinical trial with the drug does not convey or imply that based on the clinical trial data generated with the drug permission to market this drug in the country will automatically be granted to you.
- (XIX) The permission to initiate clinical trial granted under rule 22 in form CT-06 or automatic approval under rule 23 in Form CT 4A shall remain valid for a period of two years from the date of its issue, unless extended by the Central Licencing Authority.
- (XX) The firm should submit Clinical study report (CSR) to this office after completion of trial.

Yours faithfully,  
RAJEEV SINGH  
RAGHUVANSHI  
Digitally signed by RAJEEV  
SINGH RAGHUVANSHI  
Date: 2025.05.20 16:05:47  
+05'30'

(Dr. Rajeev Singh Raghuvanshi)  
Drugs Controller General (India)

**FORM CT-06**

(See rules 22, 25, 26, 29 and 30)

**PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR  
INVESTIGATIONAL NEW DRUG**

The Central Licencing Authority hereby permits **M/s G.C.Chemie Pharmie Ltd., 5C Laxmi Industrial Estate, New Link Road, Andheri(West) MUMBAI (India) - 400053** to conduct clinical trial of the new drug or investigational new drug study titled " –“A double blind, balanced, randomized, two-treatment, two-sequence, two-period, single dose, crossover, pharmacokinetic and pharmacodynamic bioequivalence study of insulin degludec and insulin aspart injection 100 units/mL of G. C Chemie Pharmie Limited, India comparing with Ryzodeg (Insulin degludec/Insulin aspart)100 units/mL of Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd, Denmark, in healthy, adult, human male subjects using Euglycemic clamp technique under fasting conditions” vide protocol number no.: AR136-24 Version 01 dated 24 Oct 2024 in the below mentioned clinical trial sites.

2. Details of new drug and clinical trial site [as per Annexure].

3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

Place: New Delhi

Date: 20.05.2025

**RAJEEV SINGH**

**RAGHUVANSHI**

Digitally signed by

RAJEEV SINGH

RAGHUVANSHI

Date: 2025.05.20 16:06:13  
+05'30'

(Dr. Rajeev Singh Raghuvanshi)  
Drugs Controller General (India)  
Central Licensing Authority

**Annexure:****Details of new drug or investigational new drug:**

Name of the new drug or investigational new drug	Insulin degludec and Insulin aspart Injection		
Therapeutic class	Antidiabetic		
Dosage form:	Solution for injection		
Composition:	Insulin degludec and Insulin aspart Injection(1ml)		
	Name of Ingredient	Function	Formulation amount
	Insulin degludec (rDNA origin) IH	Active ingredient	2.562mg/ml
	Insulin aspart (rDNA origin) IH	Active ingredient	1.050mg/ml
	Glycerin	Osmotic pressure regulator	19mg/ml
	Phenol	preservative	1.50mg/ml
	m-cresol	preservative	1.72mg/ml
	Zinc	Stabilizing agent	27.4µg/ml
	Sodium chloride	Osmotic pressure regulator	0.58mg/ml
	Hydrochloric acid	pH adjusting agent	appropriate
	Sodium hydroxide	pH adjusting agent	appropriate
	Water for injection(WFI)	solvent	Add to 1ml
	The zinc reagent in the formulation is zinc acetate dihydrate		
Indications:	Treatment of diabetes mellitus in adults		

**Details of clinical trial site:**

S. No.	Name and Address of Clinical Trial Site	Ethics Committee Details	Name of Principal Investigator
1	ADVITY Research Pvt. Ltd., 3rd & 4th Floors, Archies Continental, P. No. 2A, 3, S. No. 1094 & 1095, Adj: Kukatpally Metro station, Kukatpally, Hyderabad - 500072, Telangana, India Tel. No.: +91-40-69089999	Institutional Ethics Committee Vasavi Medical & Research Centre Vasavi Hospital, # 6-1-91, Opp. Sensation Theatre, Lakdikapool, Khairatabad, Hyderabad-500004, Telangana, India <u>EC Reg. No.</u> (ECR/139/Inst/AP/2013/RR-24)	Dr. Sowmya Bondalapati, M.D (General Medicine)

